IDbyDNA raises $20M in Series B funding for Explify diagnosis platform
Category: #business  By Saipriya Iyer  Date: 2020-01-31
  • share
  • Twitter
  • Facebook
  • LinkedIn
IDbyDNA raises $20M in Series B funding for Explify diagnosis platform

 

  • The Series B funding has reportedly been led by ARTIS Ventures and others.
  • Main motive of the funding raised is to fuel growth of company’s Explify Software Platform for the treatment of global infectious diseases.
     

California based metagenomics technology company, IDbyDNA has recently announced raising nearly USD 20 million in the Series B funding for carrying out the developments in the pathogen identification and infectious disease detection. Moreover, it has been claimed that the funding was led by ARTIS Ventures joined by Genesys Capital and various others.

According to credible sources, funds generated would be used to drive the growth of IDbyDNA’s Explify Software Platform for the global infectious disease and microbe testing industries. For the records, Explify identifies approximately more than 20 thousand microorganisms and 3 thousand rare and known pathogens. Additionally, company’s current partnerships and collaborations with the leading US and worldwide commercial labs, academic institutions, and hospitals would augment the customer adoption of Explify as one of the leading metagenomics technology platforms.

 It has been reported that the Series B funding would also be used to support the launch of CLIA-approved commercial lab at the company’s Salt Lake City facility. Speculations have it that platform’s capabilities will gain profit from this facility’s disease testing.

Guochun Liao, the co-founder and CEO of IDbyDNA reportedly quoted that the company will progressively enhance and expand its platform to facilitate the testing procedures of pathogens and microorganisms.

Meanwhile, a partner at ARTIS Ventures, Stuart Peterson, cited that the management believes in company’s technology which has hit a tipping point and is now all set to revolutionize the way it responds and tackles the antimicrobial resistance and infectious disease outbreaks. He further added that being an investor in the company’s Series A Funding round as well, the firm stood chances of being a witness to the incredible insights of IDbyDNA’s approach to metagenomic testing to enhance the infectious disease diagnosis and pathogen detection.

Source credit: https://www.biospace.com/article/releases/idbydna-raises-20-million-in-series-b-financing-to-continue-advancements-in-infectious-disease-diagnosis-and-pathogen-identification/
 

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

GE and Uniper team up to decarbonize gas-fired Uniper power plants
GE and Uniper team up to decarbonize gas-fired Uniper power plants
By Saipriya Iyer

Uniper, a renowned Germany-based global energy company, and General Electric (GE), the renowned US based conglomerate, have reportedly announced a new long-term partnership deal to decarbonize Uniper’s natural gas storage facilities and gas-fir...

Unirac announces acquisition of solar racking firm Ecolibrium Solar
Unirac announces acquisition of solar racking firm Ecolibrium Solar
By Saipriya Iyer

North American solar mounting systems provider, Unirac has recently announced that it has completed the acquisition of Ohio-based solar racking company, Ecolibrium Solar. According to reports, this purchase would broaden Unirac’s product offeri...

Atos takes quantum simulator to the next level with Atos QLM E
Atos takes quantum simulator to the next level with Atos QLM E
By Saipriya Iyer

Atos, one of the leading companies in digital transformation, has reportedly expanded its quantum solutions portfolio by offering Atos QLM E (Atos QLM Enhanced), the world’s best performing commercially available quantum simulator, with a new r...